The Food and Drug Administration (FDA) has issued a warning to physicians regarding an increased risk of heart attack and elevated cholesterol in people taking the GlaxoSmithKline HIV drug Lexiva (fosamprenavir). The FDA has sent "Dear Healthcare Professional" letters to HIV providers warning them of the increased risk of heart attacks and abnormally high cholesterol levels in patients taking a Lexiva containing regimen. The letter also warned providers of the need to monitor patients closely for fat redistribution signs and symptoms and cholesterol and triglyceride elevation during and after Lexiva use. The letter also suggested that people with other cardiac risk factors such as smoking, high blood pressure, previous heart disease, or a family history of heart disease should be monitored very closely while taking Lexiva. If you are taking Lexiva, speak with your HIV provider to see if you are at risk.
More Information
